MinorHMG-CoA reductase inhibitors (statins)×Antiplatelet agents – P2Y12 receptor inhibitors
Updated · Methodology
Mechanism
An early study (Lau et al., Circulation 2003) in 44 patients showed in vitro competition between atorvastatin and clopidogrel for CYP3A4. Subsequent large clinical trials (PROVE-IT, MIRACL, CHARISMA) did not confirm clinically significant attenuation of clopidogrel's antiplatelet activity.
Symptoms
The combination usually causes no specific symptoms. Each drug's individual side effects remain.
Management
Standard combination after acute coronary syndrome and in coronary artery disease. No dose adjustment needed. In patients at high risk of recurrent thrombosis with unclear antiplatelet activity, consider switching to ticagrelor or prasugrel (CYP3A4-independent).
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- ESC: 2023 ESC Guidelines for the management of acute coronary syndromes (2023)– Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826
- ACC/AHA: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018)– Circulation 2019;139(25):e1082–e1143
- CHARISMA Investigators: Lack of Adverse Clopidogrel-Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial (2007)– Circulation 2003;108(8):921–924; CHARISMA substudy: Am Heart J 2007;153(5):806.e1–6